Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice

To evaluate the performance of Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in a tertiary neurology clinic setting with high frequency of non-AD cases, including normal pressure hydrocephalus (NPH). There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181,...

Full description

Saved in:
Bibliographic Details
Published in:Mayo Clinic proceedings 2024-08, Vol.99 (8), p.1284-1296
Main Authors: Li, Wentao, Petersen, Ronald C., Algeciras-Schimnich, Alicia, Cogswell, Petrice M., Bornhorst, Joshua A., Kremers, Walter K., Boeve, Bradley F., Jones, David T., Botha, Hugo, Ramanan, Vijay K., Knopman, David S., Savica, Rodolfo, Josephs, Keith A., Cliatt-Brown, Christine, Andersen, Emerlee, Day, Gregory S., Graff-Radford, Neill R., Ertekin-Taner, Nilüfer, Lachner, Christian, Wicklund, Meredith, van Harten, Argonde, Woodruff, Bryan K., Caselli, Richard J., Graff-Radford, Jonathan
Format: Article
Language:English
Subjects:
Alzheimer's disease
Biological markers
Cerebrospinal fluid
Health aspects
Medical research
Medicine, Experimental
Neurology
Physiological aspects
Practice
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the performance of Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in a tertiary neurology clinic setting with high frequency of non-AD cases, including normal pressure hydrocephalus (NPH). There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181, total-Tau) from April 1, 2020, through April 23, 2021. A behavioral neurologist blinded to CSF results assigned a clinical diagnosis retrospectively on the basis of consensus criteria, and a neuroradiologist blinded to the diagnosis and CSF studies graded brain magnetic resonance images for indicators of CSF dynamics disorders. Associations between biomarkers, diagnoses, and imaging were assessed by χ2, analysis of covariance, and linear regression methods. Median age at time of testing was 67 years (range, 19 to 96 years), median symptom duration was 2 years (range, 0.4 to 28 years), and median Short Test of Mental Status score was 30 (range, 0 to 38). Clinical diagnoses significantly correlated with different CSF biomarker values (χ2=208.3; P=10e-4). p-Tau181/Aβ42 ratios above 0.023 positively correlated with Alzheimer dementia (more than individual measures). This ratio also had the best performance for differentiating Alzheimer dementia from NPH (area under the curve, 0.869). Imaging markers supportive of CSF dynamics disorders correlated with low Aβ42, p-Tau181, and total-Tau. In a heterogeneous clinical population, abnormal p-Tau181/Aβ42 ratios (>0.023) have the strongest association with Alzheimer dementia and probably represent a comorbid AD pathologic component in persons clearly matching non-AD neurodegenerative syndromes. Altered CSF dynamics were associated with lower concentrations of AD CSF biomarkers regardless of clinical diagnosis, but the ratio compensates for these changes. In the appropriate clinical setting, an isolated abnormal Aβ42 should prompt consideration of NPH.
ISSN:0025-6196
1942-5546
1942-5546
DOI:10.1016/j.mayocp.2023.12.024